Glaukos announced that Epioxa, its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, demonstrated statistically significant improvement from baseline vs. placebo in maximum corneal curvature at 12 months.
According to a company press release, this second multicenter, phase 3 confirmatory trial randomly assigned 312 eyes in a 2:1 ratio to receive Epioxa therapy or placebo/sham procedure to assess the treatment’s safety and efficacy in progressive keratoconus.
Topline results showed that Epioxa demonstrated a Kmax treatment effect of –1.00 D at 12